Filing Flows › 8-K events › Edesa Biotech
Edesa Biotech: entry into a material definitive agreement
Form 8-K filed Nov 9, 2026 · items 1.01, 1.02, 7.01
Entry into a material definitive agreementEdesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
What the filing says
On November 8, 2026, Edesa Biotech, Inc., together with its wholly owned subsidiaries (the “Company”), entered into a Collaboration and License Agreement (the “License Agreement”) with Kyorin Pharmaceutical Co., Ltd. (“Kyorin”). Pursuant to the License Agreement, the Company granted Kyorin an exclusive, royalty-bearing
Read the filing on SEC EDGAR →
What usually followsAcross 23,535 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,370. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.